GVK BIO's Response

GVK BIO is respectful of the EMA decision taken in the interest of human health.
The EMA recommendation is based on the French Agency's report that concluded duplication of check-out ECG recordings of trial participants in 9 studies. The EMA, on basis of a "doubt", has extrapolated the findings to ALL studies conducted at GVK BIO's Hyderabad Clinical facility. We believe that the action is unprecedented and highly disproportional given the following :
The French Agency states that "the electrocardiograms (ECGs) inspected are not essential given the demonstration of bioequivalence, they can only track the health of the person in clinical trials." The French Agency's recommendation has been made as a 'precautionary' measure.
The French Agency also states "the observations made during the inspection of GVK BIO's clinical activities in Hyderabad should not be extrapolated to other trial-related activities at the same site (bioanalytical, pharmacokinetic and statistical activities) or to their other site in Ahmedabad, which are not directly affected by these observations"
The EMA states "Nothing/no evidence to date has established a proven risk to human health or lack of effectiveness of the products concerned"
GVK BIO is working closely with its customers to ensure an appropriate and quick resolution to these issues.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.

The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.